Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know.

TL;DR

The FDA has issued a warning to Empower Pharmacy for allegedly mass-producing copies of popular weight-loss drugs.
Compounding pharmacies traditionally customize medications, but can copy FDA-approved drugs during declared shortages.
The FDA declared an end to the shortage of certain weight-loss drugs in 2025, but some state-licensed pharmacies continued making copies by altering dosages or adding vitamins.
Eli Lilly is suing Empower Pharmacy, alleging deceptive marketing of standardized knockoffs.
The FDA's action is significant as it's the first time the agency has addressed the line between personalized drug compounding and mass production.
Evidence cited by the FDA includes orders lacking prescriber justification for significant differences and the sheer volume of production.
The FDA's stance may prompt compounding pharmacies to re-evaluate their practices, potentially narrowing the availability of compounded weight-loss drugs.

Continue reading the original article